118,982 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners Inc. acquired a new stake in ARS Pharmaceuticals, purchasing 118,982 shares valued at approximately $1.5 million.
• Insider Sarina Tanimoto sold 37,656 shares for over $530,000, resulting in a 2.93% decrease in her position.
• ARS Pharmaceuticals' stock was downgraded from "hold" to "sell" by Wall Street Zen, with an average rating of "Buy" and a consensus price target of $31.00.

Epoch Investment Partners Inc. acquired a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 118,982 shares of the company's stock, valued at approximately $1,497,000. Epoch Investment Partners Inc. owned approximately 0.12% of ARS Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Bernard Wealth Management Corp. bought a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd bought a new position in ARS Pharmaceuticals during the first quarter valued at approximately $37,000. PNC Financial Services Group Inc. raised its position in ARS Pharmaceuticals by 78,100.0% during the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after acquiring an additional 3,905 shares in the last quarter. BNP Paribas Financial Markets bought a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $75,000. Finally, Ball & Co Wealth Management Inc. acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter valued at about $105,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $31.00.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 37,656 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $14.09, for a total value of $530,573.04. Following the completion of the sale, the insider directly owned 1,247,447 shares of the company's stock, valued at approximately $17,576,528.23. This trade represents a 2.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Karas sold 15,000 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $16.00, for a total value of $240,000.00. Following the completion of the sale, the insider directly owned 7,696 shares of the company's stock, valued at $123,136. This trade represents a 66.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 882,649 shares of company stock worth $15,773,760. 33.50% of the stock is owned by company insiders.

ARS Pharmaceuticals Stock Performance

SPRY traded down $1.24 during midday trading on Friday, reaching $11.62. The company's stock had a trading volume of 7,180,242 shares, compared to its average volume of 1,999,456. The stock has a market cap of $1.15 billion, a P/E ratio of -23.71 and a beta of 0.90. The company has a fifty day simple moving average of $16.55 and a 200 day simple moving average of $14.40. The company has a current ratio of 6.17, a quick ratio of 5.98 and a debt-to-equity ratio of 0.37. ARS Pharmaceuticals, Inc. has a twelve month low of $10.00 and a twelve month high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.05). The firm had revenue of $15.72 million during the quarter, compared to the consensus estimate of $12.92 million. ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%. Research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.